IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Terms of Agreement
SGX (now Eli Lilly) 2006 Drug discovery Agreement to develop and commercialize
BCR-ABL inhibitors for the treatment of
drug-resistant chronic myelogenous
leukemia. SGX was acquired by Eli Lilly in
August 2008.
Infinity 2006 Drug discovery Exclusive access to a range of
small-molecule inhibitors of the Bcl-2
protein family that Infinity has identified
using its DOS (Discovery Oriented
Synthesis) chemistry technology. Novartis
will pay $30m over the first two years of
the deal.
Merlion 2006 Drug discovery Merlion is to screen its library of natural
compounds against a dengue fever target
identified by Novartis. As part of the deal,
Novartis may license drug candidates from
Merlion and also has the option to develop
and commercialize compounds in other
therapeutic areas, in return for fees and
milestones.
Ablynx 2005 Therapeutic
Nanobodies
Alnylam 2005 Development of RNAi
as therapeutic
© 2009 IMS Health In cor po rated or its af fil i ates Page 133
Agreement to discover and develop
therapeutic Nanobodies against a number
of targets in a range of disease areas.
Ablynx will receive upfront fees and
funding for R&D, and it will be eligible for
milestone payments and royalties upon
commercialization. Agreement extended
for an additional year in December 2007.
Ablynx announced in February 2008 that it
has received an undisclosed milestone
payment from Novartis.
Alliance to apply Anlylam’s expertise in
RNAi on unspecified major multiple
diseases areas in Novartis’ research
portfolio. Novartis will pay Alnylam
$56.8m to cover up front payment and
the purchase of around 4.2 million
Alnylam shares (a 19.9% stake in the
firm). Alnylam will also receive research
and early development funding, milestone
payments and royalties. In July 2008, it
was reported that the alliance had been
extended for an additional year, until
October 2009.